Seagen's ADCETRIS Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival At 12 Months In Phase 2 Trial Of Patients With Early Stage Classical Hodgkin Lymphoma

Moomoo 24/7 ·  12/11/2023 15:14

– 88% of patients with advanced stage classical Hodgkin Lymphoma in trial remained progression free at 24 months –

– Investigational regimen that eliminates two commonly used chemotherapy agents, vinblastine and bleomycin, continues to show consistent safety and tolerability profile, with no cases of febrile neutropenia and no new safety signals observed –

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment